Climb Bio reported third-quarter 2026 results and updates across its experimental treatments for immune-mediated diseases. The main developments were new early-stage data for CLYM116 and budoprutug, progress in kidney-disease trials, and a cash balance the company says should fund operations into the second half of 2028.
The company also published an updated investor presentation. The financial information provided here includes its cash position and runway, but not detailed quarterly revenue or expense figures.
Key details
-
CLYM116 data support testing less-frequent dosing. In two Phase 1 studies in healthy volunteers, a single dose of at least 480 mg kept free APRIL suppressed by more than 90% through 12 weeks. After an 800 mg dose, Gd-IgA1 fell about 70% and total IgA about 60% at 12 weeks. The results support the company’s plan to study dosing every 12 weeks.
-
The healthy-volunteer safety findings were generally favorable. Climb Bio reported no dose-limiting toxicities, treatment-related serious adverse events or hypogammaglobulinemia in the CLYM116 studies. The trials were designed to assess safety and drug activity, not to establish whether the treatment benefits patients.
-
A Phase 2 CLYM116 trial in IgA nephropathy is underway. Dosing has begun in NAVIGATE-2, which is enrolling patients. The open-label study is testing an 800 mg loading dose followed by 400 mg every eight or 12 weeks. The design is intended to help determine whether an every-12-week schedule can advance into later-stage testing.
-
CLYM116 milestones are expected in 2027. Climb Bio expects initial NAVIGATE-2 results in the first half of 2027 and aims to start a global Phase 3 trial that year, subject to regulatory feedback.
-
Budoprutug showed early biological activity in primary membranous nephropathy. In the Phase 2 PrisMN study, patients receiving 200 mg showed B-cell depletion, lower levels of antibodies against PLA2R, and what the company described as immunologic remission at Week 12. These are measures of immune activity; the update did not report evidence of clinical remission in patients’ kidney disease.
-
More PrisMN data are still pending. Enrollment is ongoing, and Climb Bio expects additional results from all dose groups, including longer-term follow-up, in 2027. The company said initial observations from the 600 mg group suggested greater drug exposure, but the supplied update did not provide further details on those observations.
-
Budoprutug is also being studied in lupus. Initial Phase 1b results in systemic lupus erythematosus showed a favorable safety and tolerability profile, with no serious adverse events reported. Single doses of 10 mg to 100 mg produced dose-dependent B-cell depletion and reductions in SLEDAI-2K, a measure of lupus disease activity.
-
Further budoprutug data are expected in December. Climb Bio plans to present additional Phase 1b data from its immune thrombocytopenia study at the American Society of Hematology meeting.
-
Cash totaled $227.6 million at Sept. 30, 2026. The balance included cash, cash equivalents and marketable securities. The company expects its cash runway to extend into the second half of 2028.
Plain-English implications
CLYM116’s results provide early support for a potential once-every-12-weeks dosing schedule, while its patient trial is now underway. Budoprutug has shown immune-system effects in early studies, but the updates do not yet establish clinical benefit. The stated cash runway provides a funding horizon for the company’s planned trials and anticipated readouts.